vs
Amphastar Pharmaceuticals, Inc.（AMPH）与APOGEE ENTERPRISES, INC.（APOG）财务数据对比。点击上方公司名可切换其他公司
APOGEE ENTERPRISES, INC.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.9倍（$351.4M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 4.7%，领先8.6%），APOGEE ENTERPRISES, INC.同比增速更快（1.6% vs -1.8%），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs 2.9%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Apogee Enterprises是一家美国音频设备制造商，主营音频接口、模数与数模转换器、USB及iOS麦克风，同时还开发音频制作相关软件，产品广泛服务于专业录音、音乐创作等音频领域，在全球音频行业拥有较高的认可度。
AMPH vs APOG — 直观对比
营收规模更大
APOG
是对方的1.9倍
$183.1M
营收增速更快
APOG
高出3.4%
-1.8%
净利率更高
AMPH
高出8.6%
4.7%
两年增速更快
AMPH
近两年复合增速
2.9%
损益表 — Q4 FY2025 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $351.4M |
| 净利润 | $24.4M | $16.6M |
| 毛利率 | 46.8% | 22.4% |
| 营业利润率 | 19.4% | 7.3% |
| 净利率 | 13.3% | 4.7% |
| 营收同比 | -1.8% | 1.6% |
| 净利润同比 | -35.7% | 568.8% |
| 每股收益（稀释后） | $0.51 | $0.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHAPOG
| Q1 26 | — | $351.4M | ||
| Q4 25 | $183.1M | $348.6M | ||
| Q3 25 | $191.8M | $358.2M | ||
| Q2 25 | $174.4M | $346.6M | ||
| Q1 25 | $170.5M | $345.7M | ||
| Q4 24 | $186.5M | $341.3M | ||
| Q3 24 | $191.2M | $342.4M | ||
| Q2 24 | $182.4M | $331.5M |
净利润AMPHAPOG
| Q1 26 | — | $16.6M | ||
| Q4 25 | $24.4M | $16.5M | ||
| Q3 25 | $17.4M | $23.6M | ||
| Q2 25 | $31.0M | $-2.7M | ||
| Q1 25 | $25.3M | $2.5M | ||
| Q4 24 | $38.0M | $21.0M | ||
| Q3 24 | $40.4M | $30.6M | ||
| Q2 24 | $37.9M | $31.0M |
毛利率AMPHAPOG
| Q1 26 | — | 22.4% | ||
| Q4 25 | 46.8% | 23.8% | ||
| Q3 25 | 51.4% | 23.1% | ||
| Q2 25 | 49.6% | 21.7% | ||
| Q1 25 | 50.0% | 21.6% | ||
| Q4 24 | 46.5% | 26.1% | ||
| Q3 24 | 53.3% | 28.4% | ||
| Q2 24 | 52.2% | 29.8% |
营业利润率AMPHAPOG
| Q1 26 | — | 7.3% | ||
| Q4 25 | 19.4% | 7.1% | ||
| Q3 25 | 13.2% | 7.5% | ||
| Q2 25 | 24.2% | 2.0% | ||
| Q1 25 | 21.9% | 1.8% | ||
| Q4 24 | 24.2% | 8.4% | ||
| Q3 24 | 29.8% | 12.3% | ||
| Q2 24 | 30.3% | 12.5% |
净利率AMPHAPOG
| Q1 26 | — | 4.7% | ||
| Q4 25 | 13.3% | 4.7% | ||
| Q3 25 | 9.0% | 6.6% | ||
| Q2 25 | 17.8% | -0.8% | ||
| Q1 25 | 14.8% | 0.7% | ||
| Q4 24 | 20.4% | 6.1% | ||
| Q3 24 | 21.1% | 8.9% | ||
| Q2 24 | 20.8% | 9.4% |
每股收益（稀释后）AMPHAPOG
| Q1 26 | — | $0.78 | ||
| Q4 25 | $0.51 | $0.77 | ||
| Q3 25 | $0.37 | $1.10 | ||
| Q2 25 | $0.64 | $-0.13 | ||
| Q1 25 | $0.51 | $0.12 | ||
| Q4 24 | $0.74 | $0.96 | ||
| Q3 24 | $0.78 | $1.40 | ||
| Q2 24 | $0.73 | $1.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $39.5M |
| 总债务越低越好 | $608.7M | $232.3M |
| 股东权益账面价值 | $788.8M | $511.8M |
| 总资产 | $1.6B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.45× |
8季度趋势，按日历期对齐
现金及短期投资AMPHAPOG
| Q1 26 | — | $39.5M | ||
| Q4 25 | $282.8M | $41.3M | ||
| Q3 25 | $276.2M | $39.5M | ||
| Q2 25 | $231.8M | $32.8M | ||
| Q1 25 | $236.9M | $41.4M | ||
| Q4 24 | $221.6M | $43.9M | ||
| Q3 24 | $250.5M | $51.0M | ||
| Q2 24 | $217.8M | $30.4M |
总债务AMPHAPOG
| Q1 26 | — | $232.3M | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | $285.0M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHAPOG
| Q1 26 | — | $511.8M | ||
| Q4 25 | $788.8M | $512.3M | ||
| Q3 25 | $776.7M | $500.2M | ||
| Q2 25 | $757.5M | $481.8M | ||
| Q1 25 | $751.3M | $487.9M | ||
| Q4 24 | $732.3M | $522.1M | ||
| Q3 24 | $727.7M | $506.4M | ||
| Q2 24 | $713.3M | $480.0M |
总资产AMPHAPOG
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $917.1M | ||
| Q2 24 | $1.5B | $889.0M |
负债/权益比AMPHAPOG
| Q1 26 | — | 0.45× | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | 0.58× | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $122.5M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | 7.8% |
| 现金转化率经营现金流/净利润 | 1.35× | 7.37× |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHAPOG
| Q1 26 | — | $122.5M | ||
| Q4 25 | $32.9M | $29.3M | ||
| Q3 25 | $52.6M | $57.1M | ||
| Q2 25 | $35.6M | $-19.8M | ||
| Q1 25 | $35.1M | $30.0M | ||
| Q4 24 | $29.0M | $31.0M | ||
| Q3 24 | $60.0M | $58.7M | ||
| Q2 24 | $69.1M | $5.5M |
自由现金流AMPHAPOG
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $22.9M | ||
| Q3 25 | $47.2M | $52.4M | ||
| Q2 25 | $25.0M | $-26.9M | ||
| Q1 25 | $24.4M | $19.1M | ||
| Q4 24 | $16.6M | $22.0M | ||
| Q3 24 | $46.2M | $50.2M | ||
| Q2 24 | $63.1M | $-1.8M |
自由现金流率AMPHAPOG
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 6.6% | ||
| Q3 25 | 24.6% | 14.6% | ||
| Q2 25 | 14.3% | -7.8% | ||
| Q1 25 | 14.3% | 5.5% | ||
| Q4 24 | 8.9% | 6.4% | ||
| Q3 24 | 24.1% | 14.7% | ||
| Q2 24 | 34.6% | -0.5% |
资本支出强度AMPHAPOG
| Q1 26 | — | 7.8% | ||
| Q4 25 | 4.5% | 1.9% | ||
| Q3 25 | 2.8% | 1.3% | ||
| Q2 25 | 6.1% | 2.1% | ||
| Q1 25 | 6.3% | 3.2% | ||
| Q4 24 | 6.7% | 2.6% | ||
| Q3 24 | 7.2% | 2.5% | ||
| Q2 24 | 3.3% | 2.2% |
现金转化率AMPHAPOG
| Q1 26 | — | 7.37× | ||
| Q4 25 | 1.35× | 1.77× | ||
| Q3 25 | 3.03× | 2.41× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 12.08× | ||
| Q4 24 | 0.76× | 1.48× | ||
| Q3 24 | 1.48× | 1.92× | ||
| Q2 24 | 1.82× | 0.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
